An open-label trial of risperidone augmentation for refractory anxiety disorders

The Journal of Clinical Psychiatry
Naomi M SimonMark H Pollack

Abstract

There is a paucity of data to support "next-step" treatments for the many patients with anxiety disorders who remain symptomatic after initial pharmacotherapy. Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks. Participants were diagnosed using the Structured Clinical Interview for DSM-IV. Risperidone augmentation at a mean +/- SD dose of 1.12 +/- 0.68 mg/day (range, 0.25-3.00 mg/day) resulted in a significant reduction in anxiety symptoms across disorders as measured by the Clinical Global Impressions-Severity of Illness scale and Hamilton Rating Scale for Anxiety (HAM-A) scores and for each disorder-specific primary outcome measure-the Panic Disorder Severity Scale, the Liebowitz Social Anxiety Scale, and HAM-A-in the intent-to-treat sample. Seventy percent (21/30) of participants completed the 8-week trial, with premature discontinuation due primarily to sedation and weig...Continue Reading

Citations

Aug 30, 2008·Neuropsychiatric Disease and Treatment·Carlo Marchesi
May 6, 2014·CNS Drugs·Rachel HershenbergOlga Brawman-Mintzer
Aug 6, 2010·Current Psychiatry Reports·Dan J SteinMichael van Ameringen
Nov 6, 2007·Expert Opinion on Emerging Drugs·Nirvana S Pillay, Dan J Stein
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Arun V RavindranTricia L da Silva
Feb 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nienke C C VulinkDamiaan Denys
Apr 2, 2008·La Presse médicale·Mayena Etchegaray, Patrick Hardy
Jan 31, 2009·Depression and Anxiety·Franklin R SchneierMarc Laruelle
Sep 10, 2014·Human Psychopharmacology·Hee Ryung WangWon-Myong Bahk
Jul 8, 2011·The International Journal of Neuropsychopharmacology·Neeltje M BatelaanDan J Stein
Nov 8, 2017·Current Psychiatry Reports·Baptiste PignonAntoine Pelissolo
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Anna M DeppingStefan Leucht
Apr 22, 2011·Journal of Clinical Psychopharmacology·Carlos D LaLonde, Ryan J Van Lieshout
Sep 17, 2008·Journal of Clinical Psychopharmacology·Luísa W Bisol, Diogo R Lara
Jun 25, 2019·Depression and Anxiety·Wicher A BokmaAnton L J M van Balkom
May 15, 2009·Journal of Clinical Psychopharmacology·Tsuyoto HaradaJun Ishigooka
Jun 16, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·Yu P Sivolap
Dec 25, 2007·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Gabriela Bezerra de MenezesMárcio Versiani
Nov 24, 2020·The Mental Health Clinician·Elayne D Ansara
Apr 6, 2021·Therapeutic Advances in Psychopharmacology·Vasilios G Masdrakis, David S Baldwin
May 5, 2021·Psychiatry Research·Franck SchürhoffAndrei Szöke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.